Castle Biosciences Inc

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $858.95M
  • PE 141
  • Debt $10.20M
  • Cash $94.96M
  • EV $774.19M
  • FCF $34.54M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$6.08M
EBIT$11.56M
ROE1%
ROA2%
FCF$34.54M
Equity$441.06M
Growth Stability1
PE141.39
PEG196.16
PB1.95
P/FCF24.87
P/S2.75
Price/Cash0.11
Debt/Equity0.02
Debt/FCF0.3
Net Margins4%
Gross Margins82%
Op. Margins4%
Earnings CAGR0%
Sales Growth YoY39%
Sales Growth QoQ-1%
Sales CAGR47%
FCF CAGR3%
Equity CAGR31%
Earnings Stability-0.43
Earnings Growth YoY-133%
Earnings Growth QoQ-75%
Earnings CAGR 5Y1%
Sales CAGR 5Y46%
FCF CAGR 5Y8%
Equity CAGR 5Y28%
Earnings CAGR 3Y58%
Sales CAGR 3Y58%
Equity CAGR 3Y1%
Market Cap$858.95M
Revenue$311.88M
Assets$514.57M
Total Debt$10.20M
Cash$94.96M
Shares Outstanding27.66M
EV774.19M
Earnings Score6%
Moat Score37%
Safety Score98%
Final Score47%
Working Capital300.48M
Current Ratio7.78
Gross Profit$255.43M
Shares Growth 3y4%
Equity Growth QoQ4%
Equity Growth YoY14%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

SEC Filings

Direct access to Castle Biosciences Inc (CSTL) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Castle Biosciences Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Castle Biosciences Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%
Stability -43%
loading chart...

Castle Biosciences Inc Discounted Cash Flow

Fully customizable DCF calculator online for Castle Biosciences Inc.

= $433M
012345678910TV
fcf$35M$36M$37M$38M$39M$41M$42M$43M$45M$46M$48M$478M
DCF$32M$30M$29M$27M$25M$24M$22M$21M$20M$18M$184M
Value$433M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201812/201912/202012/202112/202212/2023TTM
Net Margins-45%6%-16%-33%-49%-26%4%
ROA-8%-1%-9%-15%-13%2%
ROE-4%-2%-8%-17%-15%1%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-5.350---00.3
Debt over Equity-0.430.380--00.02
Growth Stability------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-128%21%50%46%60%46%
Earnings YoY growth--129%-444%204%115%-14%1%
Equity YoY growth--250%388%-1%-3%-2%28%
FCF YoY growth--148%-16%-539%110%-59%8%